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PAIRACH PINTAVORN and BARBARA J. BALLERMANN
TGF-f3 and the endothelium during immune injury. During immune
injury, activation of endothelial cells by inflammatory cytokines stimulates
leukocyte adhesion to the endothelium, turns the endothelium from an
anticoagulant surface to one that is frankly procoagulant, and results in
the release of vasoactive mediators and growth factors. Cytokine activa-
tion of endothelial cells also results in increased endothelial cell TGF-f31
synthesis and enhanced activation of latent TGF-13, the latter involving a
shift of plasmin production from the apical to subendothelial surface. In
cytokine-stimulated endothelial cells, TGF-p hinders leukocyte adhesion
and transmigration via inhibition of IL-8 and E-selectin expression.
TGF-13 also profoundly diminishes cytokine-stimulated inducible nitric
oxide synthase production and instead augments endothelial nitric oxide
synthase expression. Thus, some of the TGF-13 actions on endothelium
during immune activation can viewed as immunosuppressive. TGF-J3 also
influences mechanisms of vascular remodeling during the healing phase of
immune injury. It stimulates PDGF-B synthesis by endothelial cells, causes
bFGF release from subendothelial matrix, and promotes VEGF synthesis
by non-endothelial cells. Together these mediators control angiogenesis, a
critical component of the vascular repair phenomenon. Further, endothe-
hal cell derived PDGF-B and bFGF influence the proliferation and
migration of neighboring cells. Thus, endothelial cells and TGF-p actions
on the endothelium play important roles both during the initial phase of
immune injury and during the later remodeling phase.
Quiescent, differentiated endothelium performs several impor-
tant physiologic functions. It forms a noncoagulant surface, serves
as a barrier between extravascular and intravascular compart-
ments, and produces a number of vasoactive mediators. When
necessary, endothelial cells can also display properties precisely
opposite to those normally expressed in the quiescent state.
Indeed, the endothelium tends to balance opposing actions: anti-
versus pro-coagulant, vasoconstrictor versus vasodilator, and
growth promoting versus inhibiting. Endothelium also is an
important component of the normal immue system in that it
regulates leukocyte adhesion and diapedesis into tissues. Venular
endothelium promotes lymphocyte adhesion and trafficking as
part of the ongoing immune system surveillance function [1], but
with stimulation of immune defense systems, most other endothe-
hal cells can also be activated to recruit appropriate leukocytes
[2—4]. In renal glomeruli, endothelial cell activation is a prereq-
uisite to leukocyte influx during immune-mediated injury, and
activation often results in morphologic changes such as loss of
fenestrations, swelling and endothelial cell vacuolization [I•
The strategic location of glomerular endothelium between the
mesangial area and vascular space, without intervening basement
membrane, makes it an ideal intermediary for signals between the
mesangium and the circulation. For example, immune complex
deposition within the glomerulus triggers inflammatory cytokine
production by resident glomerular cells and macrophages, which
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in turn activate endothelial cells to signal leukocyte adherance
and migration to the site of injury. Conversely, hemodynamic
forces and signaling molecules in the circulation regulate the
production of endothelial cell-derived mediators, which in turn
affect mesangial cell behavior [5—9].
Whereas the phenomenon of endothelial cell activation during
immune injury has previously been extensively reviewed [2—4, 10],
the role of transforming growth factor beta (TGF-13) in modulat-
ing endothelial cell function during immune activation has not yet
been treated in a comprehensive fashion. Enhanced local TGF-13
action has been documented in a large number of glomerular and
renal interstitial diseases, where it is plays a central role in the
fibrogenic response to injury [11, 12]. However, TGF-13 also
regulates endothelial cell responses to immune activation, often in
an inhibitory fashion (Table I). An understanding of TGF-p
actions during immune-mediated diseases might help predict
some of the consequences of TGF-J3 overproduction and also of
potential pharmacologic interruption of the TGF-/3 cascade.
Endothelial cell activation by inflammatory cytokines
Endothelial cell "activation" refers to a set of well characterized
responses by endothehial cells to inflammatory cytokines. The
most prominent mediators of endothelial cell activation are tumor
necrosis factor a (TNFa) and interleukin 113 (IL-1p), though
several components of the complement cascade, lipid mediators,
and other inflammatory cytokines also participate in eliciting the
endothelial response to immune injury [I. TNFa and IL-1p
induce endothelial cells to secrete chemokines, to express leuko-
cyte adhesion molecules, and they stimulate endothelial proco-
agulant activity [2, 10]. TNFa is produced by macrophages after
phagocytosis of opsonized particles [13, 14], upon encountering
IgG and IgA immune complexes [15], and in response to the
complement component C5a, produced during complement acti-
vation [16]. TNFa is also released by T lymphocytes during the
process of T cell receptor engagement with MHC class II bound
antigens [17, 18] and by activated polymorphonuclear neutrophils
[191. In turn, TNFa strongly stimulates IL-1/3 synthesis by mac-
rophages and by a number of other cell types, including endothe-
hal cells [10].
TNFa and IL-i 13 synthesis in the kidney
With regard to the kidney, rat mesangial cells in culture and in
vivo produce TNFa in response to bacterial liposaccharide [20—
22], and macrophages present in the mesangium synthesize TNFcs
during immune injury [22]. There is evidence for enhanced
expression and accumulation of TNFa in glomeruli of patients
with glomerulonephritis due to systemic lupus erythematosus [23],
membranous glomerulonephritis [24] IgA nephropathy [25, 26],
and ANCA-associated crescentic glomerulonephritis [27]. Also, in
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Table 1. Endothelial cell-TGF-13 interactions
Mediators of endothelial cell TGF-13 synthesis
Acute shear stress
IL-1J3, TNFcs
Integrin v133 clustering
Latent TGF-13 activation by endothelial cells
Increased PAT-I activity
Increased u-PA activity
Enhanced thrombospondin synthesis
Effects of TGF-p on cndothelial cells
Vasoactive mediator synthesis
Increased endothelin-i production
Increased C-type natriuretic peptide production
Decreased iNOS expression
Increased eNOS expression
Leukocyte recruitment
Decreased IL-8 synthesis
Diminished E-selectin expression
Growth factors
Increased endothelial PDGF-B expression
Decreased endothelial VEGF receptor expression
Enhanced VEGF expression by non-endothelial cells
bFGF release from subendothelial cell matrix
acute nephrotoxic serum nephritis in rats, both TNFa and IL-113
synthesis are induced in renal glomeruli, with TNFc preceding the
appearance of IL-1f3 [28]. Thus, in many forms of immune-
mediated glomerular disease there is evidence for local glomeru-
lar synthesis of TNFa and IL-113, the two key cytokines involved
in endothelial cell activation. TNFa is produced primarily by
inflammatory cells and non-endothelial glomerular cells, while
IL-1p is produced by endothelial cells as well [291.
Mechanisms of endothelial cell activation
Most, but not all endothelial cell responses to TNFa and IL-113
are similar, though these cytokines do not act via the same
receptor. The endothelial cell response to TNFa is elicited by
specific cell-surface receptors, members of a receptor family that
includes Fas [30, 31]. IL-1f3 receptors belong to a separate family
of proteins that share a common extracellular motif with fIbroblast
growth factor receptors [32]. Nevertheless, both TNFa and IL-ip
receptors stimulate several similar downstream events, central to
which is the activation of the nuclear transcription factor NF-KB/
Rel, which triggers the transcription of a number of genes that
control the endothelial cell inflammatory response [33]. The
mechanism of NF-KB/Rel activation has been reviewed elsewhere
[4, 33]. Upon activation, the NF-KB/Rel dimer is rapidly translo-
cated to the endothelial cell nucleus [34] where it interacts with a
number of promoters, among them those for endothelial cell
leukocyte adhesion molecules E-selectin [33, 35], VCAM-1 [36]
and ICAM-1 [37, 38], procoagulant molecules like tissue factor
1391, and chemokines like lL-8 [40]. Furthermore, it interesting
that nitric oxide (NO), a prominant vasodilatory mediator pro-
duced by endothelial cells, inhibits NFKB [41], and that shear
stress, if applied acutely, can potentiate [42] NF-KB/Rel activation
in endothelial cells.
TGF-f synthesis by endothelial cells
Cytokine stimulated TGF-13 synthesis
Like most cells, endothelial cells express TGF-131 mRNA
constitutively and release the latent protein into the extracellular
space. However, basal rates of TGF-/31 synthesis and activation by
quiescent endothelial cells appear to be low. In this regard, Phan
et al [43] reported that latent TGF-/3 secreted by unstimulated rat
pulmonary artery endothelial cells remained inactive. IL-i /3 and,
to a lesser extent, TNFa induced TGF-f31 mRNA expression and
the combination of IL-1J3 and TNFa markedly increased TGF-/31
biological activity, indicating that TGF-(31 synthesis and activation
of latent TGF-/3 are enhanced in activated endothelial cells [43].
Clustering of the matrix binding integrin aj33 also induces
TGF-p1 synthesis by endothelial cells [44]. Since undifferentiated,
but not quiescent endothelial cells use csj33 for adhesion to matrix
proteins [45], it is conceivable that endothelial cell activation and
proliferation during the repair process is associated with crj33
stimulated TGF-p1 synthesis.
Hemodynamic forces and TGF-f3 synthesis
In addition to the regulation of endothelial cell TGF-f31
synthesis by cytokines, evidence is emerging that TGF-f3 gene
transcription is also stimulated by hemodynamic forces. Endothe-
hal cell swelling, often observed in glomerulonephritis and throm-
botic microangiopathy, can significantly reduce the lumen diam-
eter of glomerular capillaries, an effect that raises shear stress at
the capillary wall. Resnick et al found a consensus sequence in the
promoter region of several genes, including that of the TGF-/31
gene, which when occupied by appropriate transcription factors,
stimulates gene transcription in response to acute increments in
shear stress in endothelial cells [46]. Activation of the shear stress
response element was shown to involve NF-KB [42]. Ohno et al
subsequently exposed cultured bovine aortic endothelial cells to
physiological levels of shear stress in vitro and showed that
TGF-f31 mRNA expression as well as TGF-p1 activity in the cell
supernatants increased [47]. It is of note that enhanced TGF-f31
expression by endothelial cells in response to both acute shear
stress and cytokines involves activation of NF-KB.
Hemodynamic forces have long been thought to participate in
the glomerular remodeling response to non-immune injury as
well. In this regard, Lee et al [48] reported an increase in TGF-f31
and angiotensinogen mRNA abundance in glomerular endothelial
cells 24 days after 5/6 renal ablation in rats. However, they found
the most significant increase in TGF-131 expression in the most
dilated capillaries at the vascular pole. Since vessel dilation
diminishes shear stress, the finding is not easy to reconcile with
those by Ohno et al [47]. Stimuli not involving shear stress, for
instance endothelial cell stretch or an endothehial cell response to
increased local angiotensin TI concentrations, may be at play in
the renal ablation model.
Activation of latent TGF-3 by endothehial cells
The three known mammalian TGF-/3 isoforms (TGF-/31, -/32
and -/33) are secreted as latent 235 to 280 kDa complexes that
consist of the —25 kDa disulfide-linked homodimer of mature
TGF-/3s, a 75 kDa latency-associated peptide and 135 to 180 kDa
binding protein [49, 50]. Latent TGF-f3 is biologically inactive and
can be activated in vitro by extreme pH, heat, ADP, plasmin,
cathepsin D, retinoid, or glycosidase treatment [49]. Both plasmin
and thrombospondin are likely candidates for in vivo activation of
TGF-f3, and in addition, immobilization of TGF-/3 at the cell
surface by the insulin-like growth factor-II/mannose-6-phosphate
receptor and a cell-surface transglutaminase participate in activa-
tion [49—53]. Biologically active TGF-J3 in turn is inactivated by
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binding to a2-macroglobulin in the circulation [54, 55] or by
decorin in the extracellular matrix [56].
TGF-j3 activation and the endothelial cell plasminogen-plasmin
system
Non-activated endothelial cells express abundant tissue type
plasminogen activator (t-PA) [57], t-PA receptors and plasmino-
gen receptors, all confined to the cell surface [58, 59] where they
cooperate to cleave and activate plasminogen. Small amounts of
urokinase-type plasminogen activator (u-PA) are also synthesized
by unstimulated endothelial cells [60]. The main role of t-PA is to
continually free the apical endothelial cell surface of any fibrin
strands that may have formed, and u-PA is concerned principally
with matrix degradation, particularly during angiogenesis. Endo-
thelial cells also produce powerful inhibitors of t-PA and u-PA,
plasminogen activator inhibitor-I and -II (PAl-I, PAl-Il) [58, 61].
PAl-I associates with endothelial cells at their basal surface by
binding to vitronectin [62], and vitronectin may be necessary for
PAl-I mediated inactivation of both t-PA and u-PA [63, 64].
During endothelial cell activation by inflammatory cytokines, t-PA
protein expression by endothelial cells is diminished while PA-I
activity increases dramatically [57, 581. Moreover, in unstimulated
endothelial cells most of the PAl-I immunoreactivity is found in
the subendothelial cell compartment, whereas most of the PAT-I
immunoreactivity appears at the apical surface of cytokine-acti-
vated endothelial cells [65]. Finally, u-PA transcription is signifi-
cantly enhanced by TNFa treatment of endothelial cells [60], and
TGF-f31 increases PAl-I activity and u-PA mRNA expression in
endothelial cells [66—68]. Taken together, these findings would
predict that activation of TGF-f3 by cytokine-stimulated endothe-
hal cells [43] must occur predominantly in the subendothelial cell
space, due both to the apical expression of PAl-I and enhanced
production basal u-PA. Furthermore, TGF-p may modulate its
own activation by regulating the plasminogen-plasmin system in
endothehial cells [67—69].
TGF-p activation by thrombospondin
Compelling evidence has also been obtained that throm-
bospondin, a glycoprotein deposited into the cell matrix by
endothehial cells [70, 711, activates latent TGF-J3 [72]. Murphy-
Ullrich and Mosher [73] demonstrated that exposure of cultured
endothelial cell to thrombospondin results in release of active
TGF-p. Also, purified thrombospondin was found to activate
latent TGF-/3 [74], an activity that has been localized to specific
domains in the thrombospondin molecule [75, 76]. However,
thrombospondin synthesis by endothehial cells is inhibited in
response to cytokine activation, and enhanced by TGF-131 stimu-
lation [71, 77].
Thus, in TNFa or IL-lp stimulated endothehial cells, enhanced
PAl-I expression and reduced thrombospondin synthesis would
tend to inhibit TGF-p activation. Nevertheless, in cells so treated
TGF-pl activation is enhanced [43]. Whether augmented u-PA
expression and relocation of PAl-I to the apical surface of
cytokine-activated endothelial cells is sufficient to explain en-
hanced TGF-f3 activation under these circumstances remains to
be determined. TGF-/3 stimulated u-PA and thrombospondin
production by endothelial cells may serve to amplify TGF-j3
activation. Also, thrombospondin derived from non-endothehial
glomerular cells is likely to play a significant role in stimulating
local TGF-j3 activation during glomerular immune injury [78, 79].
TGF-13 receptors in endothelial cells
Three classes of TGF-f3 receptor, types I, H and III are
expressed by endothelial cells [80—84]. When Dickson et al [85]
injected 25I labeled TGF-p into mice they found that vascular
endothelium represents the major site of TGF-[3 binding in vivo.
The receptor density was highest in renal glomeruli and liver and
lowest in the continuous capillaries of heart, lung, aorta, and
brain. The authors proposed that endothelium may be an impor-
tant cellular target for any active "endocrine" TGF-f3 present in
the circulation [85]
TGF-p receptor serine threonine kinases
Type I and type II TGF-13 receptors are transmembrane
serine-threonine kinases responsible for signal transduction. They
each contain an extracellular ligand binding domain, a single
transmembrane spanning domain and a cytoplasmic kinase do-
main, and they form heterodimers to initiate signaling. At least
five distinct type I receptors have been cloned [86, 87]; they differ
predominantly in the extracellular domain. So far, only one
isoform of type II TGF-p receptor has been identified [88],
though there are other proteins in the same receptor family that
interact with TGF--like mediators, for instance, activin and bone
morphogenic protein-2. The type II TGF-/3 receptor can bind
TGF-pl and TGF-133 in the absence of type III receptor, whereas
TGF-132 binds type TI receptors only in the context of the -g1ycan
type III receptor [89].
TGF-13 binding results in the formation of a heteromeric
complex between type I, type II and type III TGF-p receptors [90,
91] and a consequent phosphorylation of type I receptor by the
constitutively active type II receptor kinase. Association of type I
and 11 TGF-13 receptors appears to be necessary for signal
transduction in most cells [92, 93]. Nevertheless, evidence has
been obtained suggesting that some TGF-f3 mediated responses in
endothelial cells can be elicited by type I receptors alone. For
example, Myoken et al showed that human umbilical vein endo-
thelial cell expressed only type I receptor while fetal bovine heart
endothelial cell expressed both type I and II [94]. In the cells
expressing only type I receptors, TGF-p was mitogenic at all concen-
trations examined, whereas in cells expressing both receptors, low
concentrations of TGF-pl stimulated, and high concentrations in-
hibited proliferation [94]. Similarly, Choi and Bahlermann found
that glomerular capillary endothelial cell proliferation was stimu-
lated by TGF-131 when signaling via the type II TGF-f3 receptor
was blocked [95]. It therefore is tempting to speculate that the
absence or presence of the type II TGF-p receptor determines
whether endothelial cells respond to TGF-/3 with proliferation or
growth arrest.
Endoglin and 13-glycan
In addition to the receptor serine threonine kinases, one of two
heavily glycosylated TGF-f3 binding proteins (type III receptors),
/3-glycan or endoghin participate in receptor signaling [80, 90, 91].
The type III TGF-/3 receptors have only a short intracellular
domains without signaling motif, and function to present the
TGF-f3 ligand to the serine threonine kinase receptors. The
/3-glycan binds all TGF-J3 isoforms with near equal affinity
whereas endoglin, expressed heavily by many endothelial cells, has
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a high affinity for TGF-131 and /33, but not for TGF-p2 [96].
Indeed, type TI TGF-f3 receptors can bind TGF-/32 only in the
presence of /3-glycan [89]. Further, endoglin, but not /3-glycan can
be phosphorylated, suggesting that endoglin function may be
regulated through phosphorylatiori [801. Taken together with the
findings that some endothelial cells are unresponsive to TGF-f32
and that unresponsiveness can be overcome by overexpression of
/3-glycan, it can be concluded that endothelial cell selectivity for
TGF-/31 and TGF-f33 over TGF-/32, when it occurs, is due to the
absence of /3-glycan and expression of endoglin instead [961. A
domain between amino acids 40-82 of TGF-/3 1 has been identified
to mediate the greater affinity of TGF-/31 for endoglin compared
t0TGF-/32 [p71. Mutations in the human endoglin gene in some
patients with the Osler Weber Rondu syndrome result in wide-
spread vascular telangectasias [981.
Thus, heterogeneity in the TGF-/3 responses of endothelial cells
from various vascular beds is largely explained by the abundance
of endoglin versus 13-glycan expression [99, 100] and the finding
that mutations in endoglin are associated with abnormalities in
blood vessel structure lend support to the view that endoglin and
the TGF-f3 signaling cascade are critical components of a system
that regulates vascular morphogenesis [95, 98, 1011.
TGF-j3 modulates endothelial cell responses to inflammatory
cytokines
Chemokine synthesis and leukocyte recruitment
The endothelial response to cytokine activation is characterized
by an increase in the expression of various mediators, among them
the chemokines interleukin-8 (IL-8) and monocyte chemoattrac-
tant protein-I (MCP-1) [4]. Smith, Noack, Khew-Goodall [102]
cultured human umbilical vein endothelial cells with TGF-/31 and
showed that TNFa induced IL-8 mRNA expression and IL-8
secretion were markedly reduced. In keeping with the chemotactic
actions of IL-8 towards neutrophils, neutrophil transmigration
across the TNFa activated endothelium was also diminished by
TGF-/3 [1021.
The adhesion of leukocytes to endothelial cells during immune
activation also requires enhanced expression of specific cell-
surface receptors both on endothelial cells and on leukocytes.
Selectins mediate an initial low-affinity adhesion between endo-
thelial cells and leukocytes, which is then followed by a high
affinity interaction between leukocyte integrins and their endothe-
hal cell counter-receptors (ICAMs and VCAM-1 and PECAM-1)
[4]. Activation of endothelial cells by cytokines is associated with
a dramatic stimulation of leukocyte adhesion, which is explained
largely by a strong transcriptional activation of E-selectin, as well
as ICAM-1 and VCAM-1 expression [1031. There now is signifi-
cant evidence that TGF-/3 markedly down-regulates cytokine-
stimulated leukocyte adhesion to endothelium. For instance,
Gamble et al [104, 105] described an inhibitory effect of TGF-f3 on
neutrophil adherence to human umbilical vein endothelial cells
explained, at least in part, by inhibition of E-selectin expression.
Similarly, Cai et al [1061 found that diminished mononuclear cell
adhesion to TNFa stimulated dermal microvascular endothelial
cells in response to TGF-/3 treatment was associated with de-
creased E-selectin expression. They also suggested that reduced
Type II TGF-/3 receptor function in endothelial cells from psori-
atic lesions could account for enhanced leukocyte infiltration of
psoriatic skin [107]. A significant TGF-f3 mediated inhibition of
lymphocyte adhesion to Peyer's patch high endothelial venule
cells has also been described [108], and in a mouse model of
multiple sclerosis, administration of TGF-/31 or TGF-p2 pre-
vented T-lymphocyte accumulation, possibly mediated by reduced
lymphocyte adhesion to endothelium [109]. Nevertheless, TGF-/3
does not block cytokine-induced expression of all endothelial cell
leukocyte receptors. For instance, Gamble et al [1051 found
reduced E-slectin, but not ICAM-1 or VCAM-1 expression in
cytokine-activated endothelium, and McCarron et a! [110] found
that while TGF-/3 treatment inhibited cytokine-stimulated adhe-
sion of lymphocytes to cerebrovascular endothelial cells, the effect
was not mediated by changes in ICAM-1 expression.
Overall, TGF-/3 consistently reduces leukocyte adhesion and
transmigration accross activated endothelium. This effect appears
to be mediated by reduced endothelial cell IL-8 synthesis and
E-selectin expression. Since chemokines like IL-8 also increase
the affinity of leukocyte integrins for ICAM-1 and VCAM-1 [4], it
is conceivable that the reduced adhesiveness of leukocytes to
TGF-j3 treated endothelium also involves reduced binding via
these cell adhesion molecules (Fig. 1).
Vasoactive mediators
Cytokines also alter the release of vasoactive mediators by
endothelial cells. In most cells, including endothelial cells, TNFa
and IL-1/3 augment the expression of inducible nitric oxide
synthase (iNOS) [111, 112]. Once expressed, this enzyme pro-
duces large amounts of nitric oxide in an unregulated fashion. In
endothelial cells [111, 113, 114] as in all other cells so far
examined [115], TGF-p1 essentially blocks cytokine-stimulated
iNOS expression. Endothehial cells usually express a constitutive
form of nitric oxide synthase (eNOS), which produces NO in a
regulated fashion, usually in response to calcium-mobilizing ago-
fists and hemodynamic forces [5, 9, 116]. It is of interest that
TGF-/31 markedly induces eNOS expression in endothelial cells
[117]. Thus, IL-1/3 and TNFa-activated endothelial cells produce
large amounts of NO in an unregulated fashion, an effect that is
opposed by TGF-/3. Exposure of endothelial cells to TGF-J3 would
instead tend to promote regulated NO production.
Endothelin-1 mRNA expression and release are also stimulated
by IL-1/3 and TNFa, but contrary to the actions of TGF-p1 on
IL-8 and iNOS expression, this effect is mimicked and not
inhibited by TGF-/31 [118—124]. Further, Suga et al [125] demon-
strated that C-type natriuretic peptide mRNA expression and
activity in bovine carotid endothelial cells are augmented by
TGF-13. Thus, the effect of TGF-/3 on endothehial cell derived
vasoactive mediator release is complex, and it is not immediately
evident whether vasodilator or vasoconstrictors would tend to
predominate.
TGF-p, endothelium and the remodeling response to vascular
injury
TGF-/3 and the process of angiogenesis
In normal, mature glomeruli, endothelial cell division is a rare
event [7]. However, active endothelial cell proliferation is one of
the phenomena observed in pathological specimens from patients
with different forms of proliferative glomerulonephritis [126, 127].
In the experimental model of Habu snake venom-induced glomer-
ulonephritis, prominent endothelia! cell proliferation and new
capillary formation were observed [128]. Also, Iruela-Arispe et a!
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Fig. 1. Schematic representation of leukocyte adhesion to activated endothelium. A. The initial interaction, mediated by selectins is of low affinity.
Leukocytes tend to roll on the endothelium during this phase of attachment. B. The low affinity interaction brings leukocyte chemokine receptors (for
instance IL-S receptors) in proximity to chemokines (IL-8). Chemokine receptor activation then markedly increases both the expression and the affinity
of leukocyte integrins. C. Activated leukocyte integrins interact with cell adhesion molecules (ICAM-1,2,VCAM-l, and PECAM-1) on the endothelial
cells. This last step is necessary for spreading and chemokinesis of leukocytes through the activated endothelium. TGF-13 markedly diminishes leukocyte
adhesion and transmigration accross activated endothelium due, in part, to inhibition of E-selectin and IL-8 production. Symbols are: (ll E-selectin;
(M) Mucin (ESL-1); (41 clustered IL-8; (fl) IL-S receptor; ( leukocyte integrin; ( cell adhesion molecule (ICAM-1).
[129] reported significant endothelial cell proliferation and angio-
genesis in the repair phase of anti-Thy-I Ab mediated mesangial
proliferative glomerulonephritis, a response that was dependent,
in part, on basic fibroblast growth factor (bFGF). bFGF is a
known angiogenic growth factor released from injured endothelial
cells [1301 and stimulates glomerular endothelial cell proliferation
in vitro [131]. In addition to bFGF, up-regulation of vascular
endothelial cell growth factor and its receptor suggests that VEGF
also participates in stimulating endothelial cell proliferation after
glomerular injury [1291.
TGF-f3 also plays a prominent role in the glomerular remodel-
ing response to injury in many experimental models of glomeru-
lonephritis and in human glomerulonephritis, particularly when
excess matrix deposition and fibrosis are important features [132,
133]. Whereas TGF-f3 tends to inhibit endothelial cell prolifera-
tion and migration in two dimensional culture in vitro [69, 134,
1351, in three dimensional gels TGF-p promotes the formation of
capillary-like structures by microvascular endothelium (Fig. 2),
akin to the process of in vivo angiogenesis [136, 137]. Capillary
formation is dependent on intact type II TGF-p receptors in
glomerular capillary endothelial cells [951. Furthermore, sprout-
ing and invasion of three dimensional gels by capillaries appears
to be dependent on a cooperative effect of fibroblast growth
factors and TGF-p [138, 139]. Whereas TGF-f3 in vitro can both
inhibit endothelial cell proliferation and stimulate angiogenesis,
administration of TGF-f3 into tissues in vivo usually is angiogerlic.
For instance, Roberts et al [100] found that mice developed
fibrotic nodules containing many new blood vessels at the sites of
subcutaneous TGF-f3 injection. An in vivo angiogenic effect of
TGF-13 was similarly observed in chicken chorioallantoic mem-
branes [140]. Further evidence that TGF-J31 is necessary for
normal blood vessel formation comes from transgenic mice with
null mutations for TGF-f31 where failure of yolk sack vascular
development was observed [101]. Also, as already noted above,
mutations in endoglin, an endothelial-cell specific TGF-J3 binding
protein, results in multisystem vascular dysplasia [98].
TGF-/3 promotes angiogenesis through direct effects on endo-
thelial cells, and also through indirect actions mediated by vascu-
lar endothelial cell growth factor (VEGF). Furthermore, VEGF
synthesis by non-endothelial cells is stimulated by inflammatory
cytokines [141, 142], in keeping with a role for VEGF for blood
vessel remodeling during immune injury. VEGF is a relatively
specific endothelial cell angiogenic factor and mitogen that is
highly expressed during development. The finding that selective,
high-level VEGF expression by epithelial cells located adjacent to
highly fenestrated endothelia, including glomerular podocytes,
continues in mature animals [142—144], has been interpreted to
indicate that VEGF is important for endothelial cell fenestrae
formation. In keeping with such a function, VEGF administration
has been reported to stimulate the formation of fenestrae by
non-fenestrated capillary endothelial cells within 10 minutes after
administration in vivo [145]. Of interest, Uchida et al [146] found
B
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Fig. 2. In vitro angiogenesis by glomerular endothelial cells in response to TGF-f31. VEGF (10 ng/ml) or TGF-f31 (1 ng/mJ) were incorporated into a type
I collagen matrix and cells were cultured in the presence of bFGF (4 ng/ml) and 5% fetal bovine serum. A. FGF alone. B. VEGF + bFGF. C and D.
TGF-1 + bFGF. As can be observed, capillary sprouts invade the collagen matrix in the presence of TGF-131, but not in its absence.
that glomerular endothelial cells express both the VEGF protein
and its receptors, so that autocrine actions of VEGF could
contribute to the maintainance of glomerular endothelial cell
fenestrae.
TGF-p strongly stimulates VEGF expression and release by a
number of non-endothelial cells [147]. Indeed, enhanced angio-
genesis in response to hypoxia may involve TGF-f3 stimulated
VEGF release from hypoxic cells [142, 148]. However, whereas
TGF-J3 stimulates VEGF synthesis and release by non-endothelial
cells, Mandriota, Menoud and Pepper [149] reported that TGF-f31
treatment markedly down-regulates VEGF receptor mRNA and
inhibits VEGF receptor protein expression at the endothelial cell
surface. These findings suggest that direct effects of TGF-p on
endothelial cells may inhibit VEGF actions, and they are consis-
tent with a report of diminished fenestrae formation by endothe-
ha! cells exposed to TGF-f3 [150].
TGF-j3 and endothelial cell-derived growth factors
Endothelial cells also contribute to the vascular remodeling and
repair process by producing PDGF, bFGF and TGF-/31 [43,
151—153], which then act on non-endothelial cells in a parcrine
fashion. Basic FGF is a heparin binding growth factor produced
by endothelial cells that normally remains bound to subendothe-
ha! matrix proteoglycans [154]. bFGF is released from subendo-
thelial matrix by the endothelial cell-associated u-PA system, and
is believed to be important for invasion of matrix during angio-
genesis and to help re-establish the integrity of the endothelium
after injury [155—1 58]. Indeed, bFGF is an important local factor
necessary for the repair of the glomerular endothelium in the
model of anti-Thyl induced glomerulonephritis in rats [1291.
Since TGF-f3 markedly stimulates u-PA expression in endothelial
cells, it is likely that release of bFGF from matrix into which
endothelial cells grow is potentiated by TGF-/3 [67—69]. Also,
since mesangial cell proliferation is regulated in part by bFGF
[159—161], and since glomerular podocyte hypertrophy can be
induced by bFGF [162], it is conceivable that glomerular endo-
thelial cell injury and consequent release of bFGF from suben-
dothelial cell matrix exerts paracrine actions on both mesangial
cells and podocytes.
Endothehial cells also produce PDGFs, which are two homolo-
gous growth factors produced from distinct genes, PDGF-A and
PDGF-B. PDGF-B has potent mitogenic actions on mesangial
cells [103, 163] and is required during renal morphogenesis for the
formation of glomerular mesangial cells [164, 165]. In renal
microvascular endothehial cells, thrombin and TGF-/31 stimulate
PDGF-B synthesis [166—168], whereas bFGF significantly inhibits
synthesis and release of PDGF-B [169]. Furthermore, mechanical
injury of endothelial cell monolayers in vivo results in enhanced
local PDGF-B synthesis [170]. Since thrombin and TGF-/31 are
likely to act on glomerular endothelial cells during immune injury,
it is plausible that endothelium derived PDGF-B participates in
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glomerular remodeling during immune-mediated glomerular in-
jury [171].
TGF-f3, endothelial cell matrix synthesis and cell-matrix
interactions
The formation of blood vessels during embryonic development
and that observed during the repair phase of injury involves matrix
degradation and synthesis as well as changes in cell-matrix inter-
actions. These processes support migration and tunneling of new
blood vessels into the matrix and must be turned off when blood
vessel formation is complete, so that a quiescent, contact-inhibited
endothelium is again established. As in other cells, TGF-p has
signfIcant effects on endothelial cell matrix synthesis and cell-
matrix interactions.
As has been shown by Border and colleagues [11, 12, 172],
proteoglycan synthesis is stimulated by TGF-f31 during glomerular
injury. Although enhanced proteoglycan synthesis is thought to
involve mainly mesangial cells, glomerular endothelial cells prob-
ably contribute to this process. In this regard, Kasinath [173]
demonstrated that TGF-131 stimulates proteoglycan synthesis to a
greater degree than other proteins in glomerular endothelial cells.
Similarly, Boudreau et a! [174] showed that TGF-p augments
ductus arteriosus endothelial cell glycosaminoglycan synthesis. As
is the case for other cell types, in endothelia! cells, the synthesis of
other matrix proteins, for instance fibronectin [136] is also in-
creased.
TGF-f3 also alters the expression of endothelial cell matrix
binding integrins. Integrins are heterodimeric proteins composed
of a and f3 subunits that exhibit specificity for various binding
domains on matrix proteins [175, 176]. Selectivity is dictated by
the a/ subunit combination. Some of the matrix binding inte-
grins, for example al33, are highly promiscuous, in that they bind
almost all matrix proteins [45]. Others, for instance the collagen
receptors a1f31 and a2f31, are much more specific in their choice of
binding partner [176]. In dermal microvascular endothelial cells,
Frank et at [177] reported that TGF-/3 produced a concentration-
and time-dependent decrease in /3 integrin subunit expression.
Also, a5, a3, and a6, but not a1, a2, and a4 subunit expression was
diminished. In association with the reduced integrin expression,
Frank et al reported that TGF-J3 treatment markedly reduced
adhesion of the endothelial cells to several matrix proteins and
that endothelial cell migration was inhibited as well [177]. This is
in contrast to findings by Enenstein, Walch and Kramer [178] who
showed that TGF-13 treatment was associated with an increase in
l3 and a5 abundance in dermal microvascular endothelial cells,
and findings by Basson et at who similarly found a stimulatory
effect of TGF-f3 on f3, , and a5 integrin expression in bovine
aortic endothelial cells [179]. The a5131 integrin is the predomi-
nant fibronectin receptor, plays a major role matrix expansion in
glomerulonephritis [180], and its expression correlates with the
degree of fibronectin expression [181]. Nevertheless, whether
TGF-/3 mediated changes in a51 integrin play a role in the
endothelial cell remodeling response to immune injury remains to
be shown.
TGF-fJ and the endothelium in glomerular diseases
As noted above, PDGF is a prominant mediator of mesangial
cell proliferation in many glomerular diseases [103, 182, 183]. For
instance, in the rat model of anti-Thy-I mediated mesangial
proliferative lida et al demonstrated increased PDGF A- and
B-chain expression in glomeruli, and PDGF receptor-13 expression
markedly up-regulated [182]. That PDGF participates in this
mesangial proliferative glomerulonephritis was demonstrated by
the findings that both mesangial cell proliferation and matrix
expansion were inhibited by infusion of neutralizing PDGF anti-
body [184]. In the same model, Okuda et al [172] demonstrated
increased in TGF-p expression in diseased glomeruli, and admin-
istration of decorin or anti-TGF-/3 antibody inhibited extracellular
matrix accumulation in this model [185, 186]. TGF-13 activity also
increased in a rabbit model of anti-GBM crescentic glomerulone-
phritis [187].
In human ANCA-positive glomerulonephritis, TGF-f3, PDGF,
and the PDGF receptor-n are expressed predominantly in cres-
cents and areas of fibrosis [188]. Also, TGF-f3 mRNA and activity
are increased in supernatants of mononuclear cell cultures and in
plasma from patients with vasculitis [189]. Since macrophages are
known to be a prominent source of TGF-f31 in vivo, such findings
are not surprising. Yoshioka et al [190] also demonstrated in-
creased TGF-j31 mRNA and protein in the glomeruli of patients
with IgA nephropathy, Henoch-SchOnlein purpura, as well as
non-IgA mesangial proliferative nephritis, and focal and segmen-
tal glomerulosclerosis, though in a smaller study, Ballardie et a!
showed down-regulation of TGF-J31 in IgA nephropathy [191].
Up-regulation of PDGF and its receptor mRNA and proteins
have been found in human lupus nephritis, membranoprolifera-
tive GN, and the proliferative form of light-chain deposition
disease, as well as in patients with IgA nephropathy [103, 188].
Thus, it is evident that both TGF-J3 and PDGF participate in
tissue remodeling in many forms of glomerulonephritis.
Given the above discussion regarding TGF-f3 mediated actions
at the level of endothelial cells, it is tempting to postulate that
TGF-13, because it is present in such large abundance in diseased
glomeruli, exerts some of its actions through its effects on the
glomerular endothelium. PDGF-B is expressed by proliferating
glomerular endothelial cells, and TGF-f31 markedly stimulates
PDGF-B expression in these cells [153, 167]. In addition, mechan-
ical injury induces PDGF-B expression by endothelial cells [170].
Although mesangial cells can synthesize PDGF [144], it is not
likely that they are the only or even the major source of PDGF
during immune-mediated glomerular injury. We therefore postu-
late that glomerular endothelial cells, in addition to mesangial
cells and infiltrating macrophages, may contribute significantly to
local PDGF-B synthesis during the remodeling and healing phase
of glomerular injury, and that TGF-/3 may stimulate glomerular
endothelial cell PDGF synthesis under these circumstances.
Summary
TGF-p is emerging as one of the most complex regulators of
endothelial cell functions. Whether TGF-/3 is presented at the
apical surface of the endothelium or is produced in the subendo-
thelial cell compartment may depend, in large part, on the state of
endothelial cell activation, and the degree to which t-PA or u-PA
activity is stimulated. Although the data are sparse, it is possible
that "endocrine" as opposed to "paracrine" actions of TGF-/3 on
endothelial cells will differ, and that such differences may be
determined in part by the local TGF-j3 concentration. TGF-13 has
very significant immunosuppressive effects that are mediated, at
least in part, through its action on endothelial cells, in which the
production of inflammatory chemokines and leukocyte adhesion
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molecules is down-regulated. TGF-f3 also plays an important role
in regulating endothelial cell migration and angiogenesis, which
are integral components of the tissue repair process. Effects on
endothelial cell growth and remodeling are produced through
TGF-f3 actions on endothelial cell matrix degrading systems,
integrin expression, and matrix synthesis, and also through TGF-/3
mediated stimulation of angiogenic growth factor synthesis and
release from the subendothelial cell matrix. The TGF-13 actions on
endothelial cells also produce paracrine effects by modulating the
secretion of endothelium-derived vasoactive substances and
growth factors, for instance, endothelin-1, nitric oxide and
PDGF-B. Since the TGF-13 expression and its actions in the
kidney could potentially be modified by dietary and pharmaco-
logic interventions [11, 192, 193] it is important to further define
TGF-J3 actions, since interruption of its immunosuppressive ef-
fects on endothelium could have potentially deleterious effects.
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